Cholera Vaccine Market to Reach $207 Mn, Globally, by 2025 at 15.6% CAGR: Allied Market Research

Lack of proper sanitation, increase in awareness regarding preventive care for cholera, and development of innovative approaches for cholera vaccine drive the growth in the global cholera vaccine market

News provided by

Allied Market Research

Mar 04, 2019, 07:15 ET

PORTLAND, Oregon, March 4, 2019 /PRNewswire/ -- Allied Market Research published a report, titled, "Cholera Vaccine Market by Product (Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-Plus, and others) and End User (Hospitals & Clinics, Research & Academic Laboratories, and Others): Global Opportunity Analysis and Industry Forecast, 2018–2025." The report provides a detailed analysis on changing market trends, drivers & opportunities, key segments, market size & estimations, and competitive scenario. According to the report, the global cholera vaccine market contributed nearly $65 million in 2017 and is expected to reach $207 million by 2025, registering a CAGR of 15.6% from 2018 to 2025.

Lack of proper sanitation, increase in awareness regarding preventive care for cholera, and development of innovative approaches for cholera vaccine drive the growth in the market. However, time taken for regulatory approvals and risks related to adverse effects restrain the market growth. On the other hand, opportunities in emerging economies create new pathways in the industry.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/5177

Dukoral to maintain its dominant share by 2025

Dukoral contributed the highest market share of nearly half of the total market in 2017 and is expected to maintain its dominant share by 2025. This is due to the established pile of the oral cholera vaccine by the World Health Organization (WHO) and rise in the number of travelers to the low- and middle-income countries (LMICs). However, Vaxchora is expected to register the highest growth rate, with a CAGR of 17.2% from 2018 to 2025, owing to its benefits such as single dose immunization, reduction in adverse effects, and high efficacy rate for prevention of cholera.

Hospitals and clinics to maintain its lead status throughout the forecast period

Hospitals and clinics accounted for nearly three-fifths of the total market share in 2017 and will maintain its lead status throughout the forecast period. This is due to increase in the incidences of cholera, demand for immunization, the availability of highly-skilled and qualified professionals in the hospitals, and preference of patients. However, the research & academic laboratories segment is expected to grow at a CAGR of 16.4% during the forecast period, owing to surge in demand for cholera vaccine across the globe for more effective and cost efficient cholera vaccines.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/5177

North America to grow fastest

North America is expected to grow at the highest growth rate, with a CAGR of 15.4% from 2018 to 2025, owing to the launch of Vaxchora, the first and only oral cholera vaccine in the U.S. and the increase in immunization. However, Asia-Pacific contributed nearly two-fifths of the total market share in 2017 and will lead throughout the forecast period. This is due to rise in prevalence of cholera disease in low-and middle-income countries leading to the increase in importance of immunization, surge in healthcare spending, and upsurge in awareness regarding cholera preventive care.

Frontrunners in the industry

Leading market players discussed in the research include Valneva SE, Astellas Pharma, Inc., Emergent BioSolutions, Inc. (PaxVax, Inc.), Eubiologics Co., Ltd., Sanofi (Shantha Biotechnics Private Limited), Johnson & Johnson (Crucell), and Celldex Therapeutics, Inc.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

Vaccines Market - Global Opportunity Analysis and Industry Forecast, 2017-2023

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
[email protected]
Web: https://www.alliedmarketresearch.com